Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells.

Fan P, Tyagi AK, Agboke FA, Mathur R, Pokharel N, Jordan VC.

Cell Death Discov. 2018 Feb 12;4:15. doi: 10.1038/s41420-017-0012-7. eCollection 2018 Dec.

2.

Effect of Genistein and 17-β Estradiol on the Viability and Apoptosis of Human Hepatocellular Carcinoma HepG2 cell line.

Sanaei M, Kavoosi F, Pourahmadi M, Moosavi SN.

Adv Biomed Res. 2017 Dec 26;6:163. doi: 10.4103/abr.abr_53_17. eCollection 2017.

3.

Nitric oxide is cytoprotective to breast cancer spheroids vulnerable to estrogen-induced apoptosis.

Shafran Y, Zurgil N, Ravid-Hermesh O, Sobolev M, Afrimzon E, Hakuk Y, Shainberg A, Deutsch M.

Oncotarget. 2017 Oct 7;8(65):108890-108911. doi: 10.18632/oncotarget.21610. eCollection 2017 Dec 12.

4.

A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.

Maximov PY, Abderrahman B, Curpan RF, Hawsawi YM, Fan P, Jordan VC.

Endocr Relat Cancer. 2018 Feb;25(2):R83-R113. doi: 10.1530/ERC-17-0416. Epub 2017 Nov 21. Review.

5.

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification.

Kota K, Brufsky A, Oesterreich S, Lee A.

Cureus. 2017 Jul 6;9(7):e1434. doi: 10.7759/cureus.1434.

6.

IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.

Lui AJ, Geanes ES, Ogony J, Behbod F, Marquess J, Valdez K, Jewell W, Tawfik O, Lewis-Wambi J.

Cancer Lett. 2017 Jul 28;399:29-43. doi: 10.1016/j.canlet.2017.04.005. Epub 2017 Apr 12.

PMID:
28411130
7.

Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.

Xiong R, Zhao J, Gutgesell LM, Wang Y, Lee S, Karumudi B, Zhao H, Lu Y, Tonetti DA, Thatcher GR.

J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.

8.

Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.

Lui A, New J, Ogony J, Thomas S, Lewis-Wambi J.

BMC Cancer. 2016 Jul 16;16:487. doi: 10.1186/s12885-016-2490-z.

9.

A Raloxifene Withdrawal Response: Translational Research, Definitions, and Clinical Applications.

Jordan VC.

Integr Cancer Ther. 2016 Sep;15(3):242-4. doi: 10.1177/1534735416651329. Epub 2016 Jun 7. No abstract available.

10.

Solamargine triggers cellular necrosis selectively in different types of human melanoma cancer cells through extrinsic lysosomal mitochondrial death pathway.

Al Sinani SS, Eltayeb EA, Coomber BL, Adham SA.

Cancer Cell Int. 2016 Feb 17;16:11. doi: 10.1186/s12935-016-0287-4. eCollection 2016.

11.

Single-Molecule Sequencing Reveals Estrogen-Regulated Clinically Relevant lncRNAs in Breast Cancer.

Jonsson P, Coarfa C, Mesmar F, Raz T, Rajapakshe K, Thompson JF, Gunaratne PH, Williams C.

Mol Endocrinol. 2015 Nov;29(11):1634-45. doi: 10.1210/me.2015-1153. Epub 2015 Oct 1.

12.

Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells.

Fan P, Cunliffe HE, Maximov PY, Agboke FA, McDaniel RE, Zou X, Ramos P, Russell ML, Jordan VC.

Mol Cancer Res. 2015 Oct;13(10):1367-76. doi: 10.1158/1541-7786.MCR-14-0494. Epub 2015 Jun 26.

13.

The Impact of Endometriosis across the Lifespan of Women: Foreseeable Research and Therapeutic Prospects.

Hughes CL, Foster WG, Agarwal SK.

Biomed Res Int. 2015;2015:158490. doi: 10.1155/2015/158490. Epub 2015 May 6. Review.

14.

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Fan P, Maximov PY, Curpan RF, Abderrahman B, Jordan VC.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:245-63. doi: 10.1016/j.mce.2015.06.004. Epub 2015 Jun 5. Review.

15.

High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country.

Lin CH, Shen CY, Lee JH, Huang CS, Yang CH, Kuo WH, Chang DY, Hsiung CN, Kuo KT, Chen WW, Chen IC, Wu PF, Kuo SH, Chen CJ, Lu YS, Cheng AL.

PLoS One. 2015 Apr 24;10(4):e0124908. doi: 10.1371/journal.pone.0124908. eCollection 2015.

16.

Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA.

Hayes EL, Lewis-Wambi JS.

Breast Cancer Res. 2015 Mar 17;17:40. doi: 10.1186/s13058-015-0542-y. Review.

17.

Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.

Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J.

Breast Cancer Res. 2015 Jan 15;17:6. doi: 10.1186/s13058-014-0506-7.

18.

The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Jordan VC.

Endocr Relat Cancer. 2015 Feb;22(1):R1-31. doi: 10.1530/ERC-14-0448. Epub 2014 Oct 22. Review.

19.

Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.

Jordan VC.

J Natl Cancer Inst. 2014 Sep 30;106(11). pii: dju296. doi: 10.1093/jnci/dju296. Print 2014 Nov.

20.

Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.

Fan P, Cunliffe HE, Griffith OL, Agboke FA, Ramos P, Gray JW, Jordan VC.

Eur J Cancer. 2014 Nov;50(16):2877-86. doi: 10.1016/j.ejca.2014.08.010. Epub 2014 Sep 15.

Supplemental Content

Support Center